Aripiprazole ER is a Small Molecule owned by Otsuka Pharmaceutical, and is involved in 25 clinical trials, of which 23 were completed, and 2 are ongoing.

Aripiprazole is a atypical anti-psychotic agent. It has partial agonistic activity at dopamine D2 receptors and serotonin 5-HT1A receptors, as well as potent antagonistic activity on serotonin 5-HT2A receptors. It stabilizes dopamine and serotonin activity in the limbic and cortical system. This stabilization is useful in managing symptoms of schizophrenia and of acute manic and mixed episodes associated with bipolar I disorders.

The revenue for Aripiprazole ER is expected to reach a total of $4.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aripiprazole ER NPV Report.

Aripiprazole ER is currently owned by Otsuka Pharmaceutical. Otsuka Holdings and H. Lundbeck are the other companies associated in development or marketing of Aripiprazole ER.

Aripiprazole ER Overview

Aripiprazole (Abilify Maintena) is an atypical antipsychotic agent. It is formulated as extended release powder for suspension for intramuscular route of administration (depot). Abilify Maintena is indicated for the treatment of acutely relapsed adults with schizophrenia. Aripiprazole (Abilify maintena) is indicated for the maintenance treatment of bipolar I disorder (manic depression).

It is under development for schizophrenia and bipolar I disorder (manic depression). It was also under development for the treatment of acutely agitated patients diagnosed with dementia.

H. Lundbeck Overview

H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, France, Italy, and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.

The company reported revenues of (Danish Krone) DKK16,299 million for the fiscal year ended December 2021 (FY2021), a decrease of 7.8% over FY2020. In FY2021, the company’s operating margin was 12.3%, compared to an operating margin of 11.3% in FY2020. In FY2021, the company recorded a net margin of 8.1%, compared to a net margin of 8.9% in FY2020. The company reported revenues of DKK4,719 million for the third quarter ended September 2022, an increase of 5.5% over the previous quarter.

Quick View – Aripiprazole ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Aripiprazole ER
Administration Pathway
  • Intramuscular
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.